# Icsm Prostate Monitoring Tt

> Recommends prostate-specific antigen (PSA) testing and digital rectal examination (DRE) to monitor prostate health during testosterone therapy, following evidence-based guidelines for prostate cancer surveillance. Use when managing a patient on testosterone and questioning whether prostate checks are needed or when PSA/DRE are due.

- Skill: `dromlakhani/icsm-prostate-monitoring-tt` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/icsm-prostate-monitoring-tt`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/icsm-prostate-monitoring-tt/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/icsm-prostate-monitoring-tt

---


# Monitor prostate health with PSA and DRE during testosterone therapy

## STEP 1 — Gather Information
Collect patient demographics, testosterone therapy formulation and start date, baseline PSA and DRE results (if available), urinary/sexual symptoms, and risk factors (family history of prostate cancer, prior elevated PSA, abnormal DRE, or comorbidities affecting prostate health).

## STEP 2 — Rule In / Rule Out
Determine if the patient is currently on testosterone therapy with no known active prostate cancer and no unresolved elevated PSA or abnormal DRE requiring urologic evaluation; if yes, proceed to timing assessment, if no, defer PSA/DRE and address the contraindication first.

## STEP 3 — Classify or Stratify
Assess time since last PSA and DRE: classify as due for PSA if ≥3 months since last PSA (baseline, 3‑month, 6‑month, or yearly interval) and due for DRE if ≥3 months since last DRE (baseline, 3‑month, or 6‑month interval) per the ICSM monitoring schedule.

## STEP 4 — Decide
Order PSA and DRE if due; if PSA >4 ng/mL (or age‑specific threshold) or DRE shows nodularity, induration, or asymmetry, refer to urology for further evaluation; otherwise continue testosterone therapy and repeat testing per schedule.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on PSA/DRE to exclude prostate cancer; evaluate symptomatic patients regardless of PSA. Do not initiate testosterone in men with untreated or active prostate cancer. Do not ignore PSA velocity >0.75 ng/mL/year or abrupt changes. Avoid DRE in patients with acute anal pathology, severe thrombocytopenia, or recent prostate biopsy. Do not substitute PSA alone for combined PSA + DRE assessment.

## Concrete Clinical Example
A 58‑year‑old man begins testosterone gel for hypogonadism. Baseline PSA 0.8 ng/mL, DRE normal. At 3 months PSA 0.9 ng/mL, DRE normal. At 6 months PSA 1.0 ng/mL, DRE normal. At 12 months PSA 1.2 ng/mL (DRE not required per guideline); therapy continues with annual PSA monitoring.

**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Society for Sexual Medicine, 2025, https://doi.org/10.1093/sxmrev/qeaf036